1125758-85-1

中文名称 1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE

英文名称 A 804598

CAS 1125758-85-1

分子式 C19H17N5

分子量 315.37

MOL 文件 1125758-85-1.mol

更新日期 2024/12/15 19:35:15

1125758-85-1 结构式

基本信息物理化学性质安全数据图谱信息 1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE价格(试剂级) 常见问题列表

基本信息

中文别名

化合物CZC25146
A-804598游离态

英文别名

CS-2234
A 804598
A-804598 （(A 804598
1-cyano-2-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine
2-Cyano-1-[(1S)-1-phenylethyl]-3-(5-quinolinyl)guanidine
N-Cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine
Guanidine, N-cyano-N''-[(1S)-1-phenylethyl]-N'-5-quinolinyl-

所属类别

生物化工：激动剂抑制剂

物理化学性质

沸点498.0±47.0 °C(Predicted)

密度1.17±0.1 g/cm3(Predicted)

储存条件Keep in dark place,Sealed in dry,2-8°C

溶解度DMSO：可溶10mg/mL，澄清

酸度系数(pKa)4.52±0.12(Predicted)

形态粉末

颜色白色至米色

安全数据

危险性符号(GHS) GHS hazard pictograms

GHS06

警示词危险

危险性描述H301

防范说明P301+P310

危险品标志T

危险类别码25

安全说明45

危险品运输编号UN 2811 6.1 / PGIII

WGK Germany3

图谱信息

1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE(1125758-85-1)核磁图(¹HNMR)

1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/02/08	HY-100483	A-804598	1125758-85-1	1 mg	300元
2025/02/08	HY-100483	1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE A-804598	1125758-85-1	5mg	550元
2025/02/08	HY-100483	1-CYANO-2-[(1S)-1-PHENYLETHYL]-3-QUINOLIN-5-YLGUANIDINE A-804598	1125758-85-1	10mM * 1mLin DMSO	605元

常见问题列表

生物活性

A-804598 是一个 CNS 渗透，竞争性和选择性的 P2X7 受体拮抗剂，作用于小鼠，大鼠和人的 P2X7 受体，IC50s 分别是 9 nM, 10 nM 和 11 nM。

靶点

IC50: 9 nM (mouse P2X7 receptor), 10 nM (rat P2X7 receptor), 11 nM (human P2X7 receptor)

体外研究

Pre-incubation with A-804598 (0.1-10 μM; 1 hour) significantly attenuates BzATP-induced cell loss in a concentration-dependent manner. 3 μM A-804598 exhibits the greatest protective effect against BzATP-induced cytotoxicity.

Cell Cytotoxicity Assay

Cell Line:	microglial cell
Concentration:	0.1, 0.3, 1, 3, 10 μM
Incubation Time:	1 hour
Result:	Protected against BzATP-induced cytotoxicity in both inactivated and activated microglia.

体内研究

A chroni treatment with A-804598 (intraperitoneal injection; 30 mg/kg; five times a week) decreases the expression of LC3B-II and SQSTM1/p62 in lumbar spinal cord at end stage of disease.

Animal Model:	Adult B6.Cg-Tg (SOD1-G93A) 1Gur/J female mice
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; five times a week
Result:	Decreased SQSTM1/p62 expression.